Monday, February 01, 2021 12:32:57 PM
Great question. Bucillamine has been used in the Orient for a long time, 20 years I believe, for a variety of things. Gout and RA are examples. Could the FDA use that data and fast track for those diseases? I don't know maybe somebody else does. Covid may not be the gold here. The effectiveness of RA drugs for Covid has been hit or miss anyway. Bucillamine would have to be more effective than Remdesivir for physicians to even consider it. Yes the mechanism Bucillamine is different but physicians want to use the most effective drug. That's what they care about. All the talk on this Board about the science behind Bucillamine is pretty meaningless if it's not effective.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
